Notably, HER2-TTC has been shown to inhibit tumor growth in HER2-low colorectal cancer (CRC) xenografts (9), highlighting its potential as an alternative treatment option for HER2-low cancers. This evidence concerns the gene ERBB2 and colorectal cancer.